APELLIS PHARMACEUTICALS INC (APLS) Stock News

USA - NASDAQ:APLS - US03753U1060 - Common Stock

25.525 USD

+1 (+4.1%)

Last: 10/20/2025, 10:39:08 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

APLS Latest News, Press Relases and Analysis

All

Press Releases

4 hours ago - By: Apellis Pharmaceuticals, Inc.

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

4 hours ago - By: Apellis Pharmaceuticals, Inc.

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

4 days ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

4 days ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

5 days ago - By: Benzinga

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 11 Analysts

24 days ago - By: Benzinga

12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know

2 months ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

2 months ago - By: Stocktwits

News Image

Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary

2 months ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

3 months ago - By: Yahoo Finance - Mentions: NVS C NOVN

Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target

3 months ago - By: Stocktwits - Mentions: GS MS

Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug

3 months ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

3 months ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

3 months ago - By: Stocktwits - Mentions: MS

Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals

3 months ago - By: Apellis Pharmaceuticals, Inc.

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

3 months ago - By: Apellis Pharmaceuticals, Inc.

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

3 months ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

3 months ago - By: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

3 months ago - By: Zacks Investment Research - Mentions: SNY ARVN AKRO

Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag

3 months ago - By: Apellis Pharmaceuticals, Inc.

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

3 months ago - By: Apellis Pharmaceuticals, Inc.

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

4 months ago - By: Yahoo Finance - Mentions: MS

Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating

4 months ago - By: Yahoo Finance

Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing

4 months ago - By: Yahoo Finance - Mentions: AQST

H.C. Wainwright Reaffirms Buy on Aquestive Therapeutics, Inc. (AQST) After FDA Approval

4 months ago - By: Apellis Pharmaceuticals, Inc.

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

4 months ago - By: Apellis Pharmaceuticals, Inc.

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)